Gemcitabine and docetaxel for epithelioid sarcoma: Results from a retrospective, multi-institutional analysis

Oncology (Switzerland)

Volumn 87, Issue 2, 2014, Pages 95-103

  Pink, Daniel ^a   Richter, Stephan ^b   Gerdes, Sebastian ^c   Andreou, Dimosthenis ^d   Tunn, Per Ulf ^a   Busemann, Christoph ^e   Ehninger, Gerhard ^b   Reichardt, Peter ^a   Schuler, Markus K ^b  

^a HELIOS KLINIKUM BERLIN BUCH   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^e UNIVERSITY MEDICINE GREIFSWALD   (Germany)

Author keywords

Chemotherapy; Combination chemotherapy; Docetaxel; Epithelioid sarcoma; Gemcitabine; Palliative chemotherapy; Sarcoma; Soft tissue sarcoma

Indexed keywords

DOCETAXEL; GEMCITABINE;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CLINICAL ARTICLE; EPITHELIOID SARCOMA; FEMALE; HUMAN; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR REGRESSION; CANCER PATIENT; CANCER REGRESSION; DRUG EFFICACY; MULTICENTER STUDY (TOPIC); RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SARCOMA; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 84903872180     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000362602     Document Type: Article

References (26)

1. Ross HM, Lewis JJ, Woodruff JM, Brennan MF: Epithelioid sarcoma: clinical behavior and prognostic factors of survival. Ann Surg Oncol 1997; 4: 491-495.
2. Bos GD, Pritchard DJ, Reiman HM, Dobyns JH, Ilstrup DM, Landon GC: Epithelioid sarcoma. An analysis of fiftyone cases. J Bone Joint Surg Am 1988; 70: 862-870.
3. Mazeron JJ, Suit HD: Lymph nodes as sites of metastases from sarcomas of soft tissue. Cancer 1987; 60: 1800-1808.
4. Riad S, Griffin AM, Liberman B, Blackstein ME, Catton CN, Kandel RA, et al: Lymph node metastasis in soft tissue sarcoma in an extremity. Clin Orthop Relat Res 2004;426: 129-134.
5. Prat J, Woodruff JM, Marcove RC: Epithelioid sarcoma: an analysis of 22 cases indicating the prognostic significance of vascular invasion and regional lymph node metastasis. Cancer 1978; 41: 1472-1487.
6. Wolf PS, Flum DR, Tanas MR, Rubin BP, Mann GN: Epithelioid sarcoma: the University of Washington experience. Am J Surg 2008; 196: 407-412.
7. Gasparini P, Facchinetti F, Boeri M, Lorenzetto E, Livio A, Gronchi A, et al: Prognostic determinants in epithelioid sarcoma. Eur J Cancer 2011; 47: 287-295.
8. Chase DR, Enzinger FM: Epithelioid sarcoma. Diagnosis, prognostic indicators, and treatment. Am J Surg Pathol 1985; 9: 241-263.
9. Jawad MU, Extein J, Min ES, Scully SP: Prognostic factors for survival in patients with epithelioid sarcoma: 441 cases from the SEER database. Clin Orthop Relat Res 2009; 467: 2939-2948.
10. Daigeler A, Kuhnen C, Moritz R, Stricker I, Goertz O, Tilkorn D, et al: Lymph node metastases in soft tissue sarcomas: a single center analysis of 1,597 patients. Langenbecks Arch Surg 2009; 394: 321-329.
11. Spillane AJ, Thomas JM, Fisher C: Epithelioid sarcoma: the clinicopathological complexities of this rare soft tissue sarcoma. Ann Surg Oncol 2000; 7: 218-225.
12. Collin C, Godbold J, Hajdu S, Brennan M: Localized extremity soft tissue sarcoma: an analysis of factors affecting survival. J Clin Oncol 1987; 5: 601-612.
13. Wright S, Armeson K, Hill EG, Streck C, Leddy L, Cole D, et al: The role of sentinel lymph node biopsy in select sarcoma patients: a meta-analysis. Am J Surg 2012; 204: 428-433.
14. Andreou D, Tunn P-U: Sentinel node biopsy in soft tissue sarcoma. Recent Results Cancer Res 2009; 179: 25-36.
15. Shimm DS, Suit HD: Radiation therapy of epithelioid sarcoma. Cancer 1983; 52: 1022-1025.
16. Baratti D, Pennacchioli E, Casali PG, Bertulli R, Lozza L, Olmi P, et al: Epithelioid sarcoma: prognostic factors and survival in a series of patients treated at a single institution. Ann Surg Oncol 2007; 14: 3542-3551.
17. Jones RL, Constantinidou A, Olmos D, Thway K, Fisher C, Al-Muderis O, et al: Role of palliative chemotherapy in advanced epithelioid sarcoma. Am J Clin Oncol 2012; 35: 351-357.
18. Tariq Z, Ghose A, Bawany MZ, Saeed B, Mohamed I, Harmon D: A case report of complete remission of pulmonary metastases from epithelioid sarcoma to navelbine chemotherapy. Am J Ther 2012; 19:e95-e97.
19. Anderson SE, Keohan ML, D'Adamo DR, Maki RG: A retrospective analysis of vinorelbine chemotherapy for patients with previously treated soft-tissue sarcomas. Sarcoma 2006; 2006: 15947.
20. Casanova M, Ferrari A, Collini P, Bisogno G, Alaggio R, Cecchetto G, et al: Epithelioid sarcoma in children and adolescents: a report from the Italian Soft Tissue Sarcoma Committee. Cancer 2006; 106: 708-717.
21. Pautier P, Floquet A, Penel N, Piperno-Neumann S, Isambert N, Rey A, et al: Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study). Oncologist 2012; 17: 1213-1220.
22. Verschraegen CF, Arias-Pulido H, Lee S-J, Movva S, Cerilli LA, Eberhardt S, et al: Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen. Ann Oncol 2012; 23: 785-790.
23. Kaya AO, Büyükberber S, Ozkan M, Alki? N, Sevinc A, Ozdemir NY, et al: Efficacy and toxicity of gemcitabine plus docetaxel combination as a second line therapy for patients with advanced stage soft tissue sarcoma. Asian Pac J Cancer Prev 2012; 13: 463-467.
24. Maki RG, Wathen JK, Patel SR, Priebat DA, Okuno SH, Samuels B, et al: Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol 2007; 25: 2755-2763.
25. Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C, et al: Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 2002; 20: 2824-2831.
26. Hensley ML, Blessing JA, Mannel R, Rose PG: Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol Oncol 2008; 109: 329-334.